Abstract

 COVID 19 or novel Corona Virus Disease is a recently declared pandemic which has taken the world by a storm, and not in a good way. It is a rapidly transmissible viral infection which was first reported in Wuhan province of China and has rapidly affected a large part of the world. It has led to a never seen before health crisis at global level and requires urgent attention of one and all. This narrative review aims to summarize the pertinent aspects of this disease and may be helpful in offering a bird’s eye view and insight to the present status of COVID-19 in an easily understandable way.

Keywords: Corona Virus; SARS-COVID-2; COVID -19; Novel Corona Virus

References

1. Shereen MA., et al. “COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses”. Journal of Advanced Research 24 (2020): 91-98.
2. Cui J., et al. “Origin and evolution of pathogenic coronaviruses”. Nature Reviews Microbiology 3 (2019): 181-192.
3. Lai C-C., et al. “Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges”. International Journal of Antimicrobial Agents (2020): 105924.
4. Organization WH. “Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, 2 March 2020”. World Health Organization (2020).
5. Zhong N., et al. “Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003”. The Lancet9393 (2003): 1353-1358.
6. Wang N., et al. “Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP$”. Cell Research 8 (2013): 986.
7. Singhal T. “A Review of Coronavirus Disease-2019 (COVID-19) ”. The Indian Journal of Pediatrics4 (2020): 281-286.
8. Li Q., et al. “Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia”. The New England Journal of Medicine (2020).
9. Chen N., et al. “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study”. Lancet 395 (2020): 507-513.
10. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China”. Lancet 395 (2020): 497-506.
11. Wang D., et al. “Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China”. The Journal of the American Medical Association (2020).
12. Guan WJ., et al. “Clinical characteristics of coronavirus disease 2019 in China”. The New England Journal of Medicine (2020).
13. Zhen J. “SARS-CoV-2: an Emerging Coronavirus that Causes a Global Threat”. International Journal of Biological Sciences 16 (2020): 1678-1685.
14. Xu X., et al. “Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission”. Science China Life Sciences (2020).
15. Centers for Disease Control and Prevention (CDC). “Coronavirus Disease 2019 (COVID-19)”. Atlanta: CDC (2020).
16. Jin YH., et al. “A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus [2019-nCoV] infected pneumonia [standard version] ”. Military Medical Research 7 (2020): 4.
17. Chen Z-M., et al. “Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus”. World Journal of Pediatrics (2020): 1-7.
18. Liu C., et al. “Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases”. ACS Central Science 6 (2020): 315-331.
19. Li G and Clercq ED. “Therapeutic options for the 2019 novel coronavirus (2019-nCoV)”. Nature Reviews Drug Discovery (2020).
20. Cortegiani A. “A systematic review on the efficacy and safety of Chloroquine for the treatment of COVID-19”. The Journal of Critical Care (2020): 30390-30397.
21. Sanders JM., et al. “Pharmacological treatments for Corona virus Disease 2019 (COVID 19)”. The Journal of the American Medical Association (2020).
22. Sheahan TP., et al. “Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses”. Science Translational Medicine (2017): 9.
23. Mulangu S., et al. “A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics”. The New England Journal of Medicine 381 (2019): 2293-2303.
24. Grein J., et al. “Compassionate use of Remdesivir for patients with severe COVID-19”. The New England Journal of Medicine (2020).
25. Nukoolkarn V., et al. “Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors”. Journal of Theoretical Biology 254 (2008): 861-867.
26. Zha L., et al. “Corticosteroid treatment of patients with corona virus disease (COVID 19) ”. Medical Journal of Australia (2019).

Citation

Citation: Amita Aditya and Priyam Aditya. “Corona Virus Disease (COVID) 2019: A Pandemic that Shook the World!". Acta Scientific Medical Sciences 4.6 (2020): 79-81.

Copyright

Copyright: © 2020 Amita Aditya and Priyam Aditya. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.